RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MALVERN, Pa., Nov. 22, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that management will host investor meetings during:
- Citi’s 2016 Global Healthcare Conference in New York, NY on Thursday, December 8, 2016
- Guggenheim’s 2016 Annual Healthcare Conference in Boston, MA on Tuesday, December 13, 2016
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting Aclaris’ website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Vice President / Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
